drugset
drugset / Trial / NCT01309477

The Efficacy and Tolerance of Tacrolimus Sustained-release Capsules on Refractory Nephrotic Syndrome (RNS)

NCT01309477 ↗

Phase 3 Completed 20 enrolled Sun Yat-sen University
Non-randomizedSingle-groupOpen-labelTreatment

Summary

It is a pilot study to explore the efficacy and safety of Tacrolimus Sustained-release Capsules (ADVAGRAF) on 6-month induction therapy of Refractory Nephrotic Syndrome (RNS).

Timeline

Start
2011-01
Primary completion
2011-10
Completion
2011-10

Drugs

EvaluationDrugModalityDoseRoute
Subject Tacrolimus Small molecule 0.05 mg/kg Oral
Subject Tacrolimus Small molecule 0.1 mg/kg Oral

Indications

nephrotic syndrome